A recent study has demonstrated that in non-alcoholic fatty liver disease, inhibition of CD36 palmitoyl modification increases mitochondrial FAO by activating AMPK, which reduces inflammation in the liver tissue20,49. Here, CD36 is linked to metabolic dysfunction-associated steatotic liver disease.